Wu Jing, Yin Li, Jiang Ning, Guo Wen-Jie, Gu Jia-Jia, Chen Meng, Xia You-You, Wu Jian-Zhong, Chen Dan, Wu Jian-Feng, Wang De-Jun, Zong Dan, Zhang Nan, Ding Kai, Huang Teng, He Xia
Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, 42 Bai Zi Ting Road, Nanjing, Jiangsu 210000, China.
Research Center of Clinical Oncology, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, Nanjing, Jiangsu, China.
Exp Cell Res. 2015 Nov 1;338(2):232-8. doi: 10.1016/j.yexcr.2015.08.006. Epub 2015 Aug 20.
MiR-145 is downregulated and functions as a tumor suppressor in many malignancies. In this study, the biological function, molecular mechanism, and direct target genes of miR-145 in nasopharyngeal carcinoma (NPC) cells were investigated. Cell survival was detected by cell viability assay, and cell cycle was determined through flow cytometry. Invasion and migration of NPC cells were examined using cell invasion and wound healing assays, respectively. A disintegrin and metalloproteinase 17 (ADAM17) was verified as the target of miR-145 through luciferase reporter assay, qRT-PCR, and Western blot analysis. In NPC cell lines, miR-145 expression was significantly downregulated and ADAM17 protein expression was upregulated. ADAM17 was downregulated at the post-transcriptional level by miR-145 via the binding site of ADAM17-3'UTR. Transfection with miR-145 mimic suppressed cell growth and induced cell cycle arrest in the G0/G1 phase by upregulating key G0/G1 phase regulators, namely, p53 and p21. MiR-145 also inhibited cellular migration and invasion through targeting ADAM17 involving the regulation of EGFR and E-cadherin. Knockdown of ADAM17 elicited similar effects to that of miR-145 on NPC cells. This study reveals that miR-145 suppressed the invasion and migration of NPC cells by targeting ADAM17. Thus, miR-145 could be a therapeutic target for NPC.
MiR-145在许多恶性肿瘤中表达下调并发挥肿瘤抑制作用。在本研究中,对miR-145在鼻咽癌(NPC)细胞中的生物学功能、分子机制及直接靶基因进行了研究。通过细胞活力测定检测细胞存活情况,通过流式细胞术确定细胞周期。分别使用细胞侵袭和伤口愈合试验检测NPC细胞的侵袭和迁移能力。通过荧光素酶报告基因检测、qRT-PCR和蛋白质印迹分析验证解整合素金属蛋白酶17(ADAM17)为miR-145的靶标。在NPC细胞系中,miR-145表达显著下调,ADAM17蛋白表达上调。miR-145通过ADAM17-3'UTR的结合位点在转录后水平下调ADAM17。转染miR-145模拟物可通过上调关键的G0/G1期调节因子p53和p21来抑制细胞生长并诱导细胞周期阻滞在G0/G1期。miR-145还通过靶向ADAM17调节表皮生长因子受体(EGFR)和E-钙黏蛋白,从而抑制细胞迁移和侵袭。敲低ADAM17对NPC细胞产生与miR-145类似的作用。本研究表明,miR-145通过靶向ADAM17抑制NPC细胞的侵袭和迁移。因此,miR-145可能成为NPC的治疗靶点。